Hillstream BioPharma Partners with Sapien Biosciences

Jun 27, 2022 By MarketDepth

Biotechnology Breaking Healthcare Investing What's Hot

Meeting in front of windows black and white

Hillstream BioPharma, Inc. (Nasdaq: HILS) today announced that it has begun a collaboration with Sapien Biosciences to evaluate the synergy of HSB-1216 with immune checkpoint inhibitors.

“We are initiating studies, in collaboration with Sapien Biosciences, to determine the synergy between HSB-1216, our ferroptosis inducer and nivolumab, an anti-PD1 antibody.”

Randy Milby, Hillstream’s Chief Executive Officer

Treatment with immune checkpoint inhibitors (ICIs) induces the effector function of T cells in the tumor microenvironment (TME). Activated T cells accumulated in TME then kill tumor cells mainly by enhancing cell death through the granzyme pathway and by releasing interferon gamma (IFN) from CD8+ T cells, according to the press release.

“We are excited to extend our collaboration with Hillstream Biopharma to evaluate potential synergy between their HSB-1216 molecule and ICIs using our expertise in establishing patient tissue-derived cell models in oncology, immunology and Immune-oncology. Previously, Sapien demonstrated potent anti-cancer activity of HSB-1216 in primary triple negative breast cancer cells which were presented at AACR 2020.”

Dr. Jugnu Jain, CEO, Sapien Biosciences